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Background & Aims: Cholangiocarcinoma (CCA) is a cancer of
the hepatic bile ducts that is rarely resectable and is associated
with poor prognosis. Tumour necrosis factor-like weak inducer
of apoptosis (TWEAK) is known to signal via its receptor fibro-
blast growth factor-inducible 14 (Fn14) and induce cholangiocyte
and myofibroblast proliferation in liver injury. We aimed to
characterise its role in CCA.
Methods: The expression of the TWEAK ligand and Fn14 re-
ceptor was assessed immunohistochemically and by bulk RNA
and single cell transcriptomics of human liver tissue. Spatio-
temporal dynamics of pathway regulationwere comprehensively
analysed in rat and mouse models of thioacetamide (TAA)-
mediated CCA. Flow cytometry, qPCR and proteomic analyses of
CCA cell lines and conditioned medium experiments with pri-
mary macrophages were performed to evaluate the downstream
functions of TWEAK/Fn14. In vivo pathway manipulation was
assessed via TWEAK overexpression in NICD/AKT-induced CCA
or genetic Fn14 knockout during TAA-mediated carcinogenesis.
Results: Our data reveal TWEAK and Fn14 overexpression in
multiple human CCA cohorts, and Fn14 upregulation in early
TAA-induced carcinogenesis. TWEAK regulated the secretion of
factors from CC-SW-1 and SNU-1079 CCA cells, inducing polar-
isation of proinflammatory CD206+ macrophages. Pharmacolog-
ical blocking of the TWEAK downstream target chemokine
monocyte chemoattractant protein 1 (MCP-1 or CCL2) signifi-
cantly reduced CCA xenograft growth, while TWEAK over-
expression drove cancer-associated fibroblast proliferation and
collagen deposition in the tumour niche. Genetic Fn14 ablation
significantly reduced inflammatory, fibrogenic and ductular re-
sponses during carcinogenic TAA-mediated injury.
Conclusion: These novel data provide evidence for the action of
TWEAK/Fn14 on macrophage recruitment and phenotype, and
cancer-associated fibroblast proliferation in CCA. Targeting
TWEAK/Fn14 and its downstream signals may provide a means
to inhibit CCA niche development and tumour growth.
Lay summary: Cholangiocarcinoma is an aggressive,
chemotherapy-resistant liver cancer. Interactions between
tumour cells and cells that form a supportive environment for
the tumour to grow are a source of this aggressiveness and
resistance to chemotherapy. Herein, we describe interactions
between tumour cells and their supportive environment via a
chemical messenger, TWEAK and its receptor Fn14. TWEAK/Fn14
alters the recruitment and type of immune cells in tumours,
increases the growth of cancer-associated fibroblasts in the
tumour environment, and is a potential target to reduce tumour
formation.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Cholangiocarcinomas (CCAs) are aggressive hepatic malig-
nancies, typically adenocarcinomas morphologically resembling
hepatobiliary epithelium, expressing cytokeratin (CK)7 and CK19
but not CK20 or Hep-Par1.1–3 CCA occurs at all regions of the
biliary tree and is classified according to anatomical location;
intrahepatic (iCCA; 20%), perihilar (50–60%) or distal (20–30%).3,4
Keywords: Cholangiocarcinoma; Liver cancer; TWEAK; Fn14; Tumour-associated
macrophage; Cancer-associated fibroblast.
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Hepatic and Biliary Cancer
CCA remains clinically challenging because of late-stage pre-
sentation, chemotherapy resistance, and high post-surgery
recurrence.3 Consequently, 5-year survival rates remain below
25%.5
CCA develops a characteristic thick, fibrous stroma composed
of a-smooth muscle actin (aSMA)-expressing cancer-associated
fibroblasts (CAFs), tumour-associated macrophages (TAMs),
neutrophils and vascular endothelial cells.3 Stromal cells interact
with neoplastic ducts via several signals including Wnt,6,7
Notch,8,9 platelet-derived growth factor,10,11 stromal-derived
factor-1/C-X-C chemokine receptor type-412,13 and numerous
cytokines, to support growth, evasion of apoptosis and promote
metastatic progression via modulation of AKT and ERK path-
ways.13–15 CD14+/CD16+ peripheral blood monocytes are elevated
in patients,16 and are recruited to tumour areas, where they
differentiate into TAMs.17,18 TAM infiltration is correlated with
tumour recurrence, metastasis and decreased survival.17,19 Fluo-
rescently tagged bone marrow-derived macrophages comprise
the majority of CD206+ TAMs in a rat CCA model, and secrete
tumour-feeding Wnt ligands.7 Ablating TAMs significantly re-
duces tumour formation, highlighting the importance of
macrophage-derived factors in maintaining CCA.7
The tumour necrosis factor (TNF)-like weak inducer of
apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14)
pathway acts by activating NF-jB/MAPK/PI3K/AKT downstream
signalling20 to regulate proliferation, survival, inflammation and
angiogenesis. TWEAK is ubiquitously expressed by macrophages
in the adult liver, with signalling modulated by dynamic regu-
lation of Fn14 during injury and repair.20,21 TWEAK initiates non-
hepatocyte-mediated regeneration via canonical NF-jB-induced
cholangiocyte proliferation21,22 and drives fibrosis-mediating
hepatic stellate cell proliferation within the injury niche.23
TWEAK-expressing macrophages were recently identified as
key drivers of fibrosis, controlling Fn14+ HSC proliferation in
human cirrhotic liver.24 TWEAK also stimulates proliferation of
hepatocellular carcinoma (HCC) cell lines,25 potentiating a role in
liver cancer growth.
We hypothesised that the principal role of TWEAK during
chronic liver disease and CCA development may be 2-fold: (i) to
act as a canonical NF-kB pathway-driven mitogen controlling
neoplastic duct and CAF proliferation and (ii) to induce NF-kB-
driven chemotaxis-associated signalling during the establish-
ment, maintenance and progression of CCA. We demonstrate
that the TWEAK/Fn14 pathway is increasingly expressed during
multi-species CCA development, regulating proliferation,
migration and polarisation of cells, including macrophages and
CAFs in the tumour niche, establishing TWEAK/Fn14 signalling as
a novel, therapeutically targetable driver of CCA development.
Materials and methods
Study approval
Animal experiments were approved by the University of Edin-
burgh animal ethics committee with U.K. Home Office approval
(70/7847, 70/8150, P231C5F81) or performed according to the
Australian code for the care and use of animals for scientific
purposes at Curtin University (AEC_2014_29). Retrospectively
collected specimens were obtained from the National Health
Service Lothian Scottish Academic Health Sciences Collaboration
BioResource and healthy liver from the Edinburgh Medical
Research Council Sudden Death Tissue Bank (10/H0716/3). Hu-
man blood was collected under ethical approval from the
University of Edinburgh (15-HV-013). All human tissue samples
were collected with informed consent.
For further details regarding the materials and methods used,
please refer to the CTAT table and supplementary information.
Results
TWEAK and Fn14 upregulation in multi-species CCA
We assessed Fn14 expression in archival CCA samples and
interrogated publicly available mRNA expression data to ascer-
tain whether the TWEAK/Fn14 pathway was overexpressed in
CCA, and to define cell type interactions of ligand and receptor. In
a cohort of pathologically confirmed human iCCA cases, Fn14 was
highly expressed by malignant epithelia, localising at the surface
of these cells. Lower expression was observed in bile ducts in
surrounding areas of non-tumour liver tissue, with diffuse
staining in hepatocytes. Fn14 was identifiable in endothelial cells
within portal triads. Positive stromal cell staining consistent with
CAFs was observed in a subset of samples (Fig. 1A). Quantifica-
tion confirmed increased Fn14 expression in CCA vs. non-CCA
areas (Fig. 1B), corroborated by interrogation of publicly avail-
able transcriptomic data. In a single cell RNA-sequencing dataset
(GSE12544926), Fn14 was mainly expressed by malignant cells,
and subsets of CAFs and hepatic progenitor cells (HPCs). TWEAK
expression was mainly observed in a subset of TAMs in iCCA
(Fig. 1C). Fn14 and TWEAK were significantly upregulated in
tumour tissue vs. non-involved liver in the TCGA-Chol cohort
(Fig. S1A) and in a microarray dataset (GSE2656627 Fig. S1B).
We then assessed the distribution of Fn14 in PanCK+ tumour
epithelia and aSMA+ CAFs in an iCCA tissue microarray, where
42.50% of tumour cells (n = 83 samples containing PanCK+ cells)
and 62.64% of CAFs (n = 79 samples containing aSMA+ CAFs)
expressed Fn14 (Fig. 1D). We observed a greater proportion of
Fn14+ CCA cells in well-differentiated (grade 1) vs. poorly
differentiated (grade 3) iCCAs, but no association between
tumour grade and the proportion of Fn14+ CAFs (Fig. 1D). No
association was observed between TNM stage and proportion of
Fn14+ cells (Fig. S1C), supported by assessment of TCGA-Chol
samples with respect to TNM stage (Fig. S1D).
Since archival human tissue samples represent end-stage
CCA, we performed time course analyses to observe the tem-
poral relationship of TWEAK/Fn14 expression to CCA develop-
ment using rodent models of thioacetamide (TAA)-mediated
injury (Fig. 2A). Histological examination of Fn14-stained serial
sections by a specialist liver histopathologist found that Fn14 was
readily identifiable in dysplastic biliary lesions and early CCA
(10–18 weeks; Fig. S2A). Like human data, Fn14 was observed at
the cell surface of biliary lesions/CCA cells, some endothelial cells
and transiently in damaged hepatocytes (Fig. S2). Fn14 was
transiently upregulated in PanCK+ ducts and surrounding
damaged hepatocytes at 10 weeks (Fig. 2B and Fig. S2A), which
reduced as injury progressed and more PanCK+ cells were
detected. As malignancy developed, subsets of PanCK+ cells
expressing Fn14 emerged. Fn14 expression continued in CCA
epithelia but not in non-malignant ducts (Fig. 2B and Fig. S2B).
Biphasic Fn14 expressionwas mirrored transcriptionally, peaking
at 10 and 20 weeks of TAA treatment. TWEAK mRNA increased
steadily over the time course (Fig. 2C). Transcripts of the pro-
fibrotic markers collagen type 1a1, transforming growth factor-
b1 (TGF-b1), tissue inhibitors of metalloproteinases (Timp1,
Timp2) and matrix metalloproteinases (MMP2, MMP9) exhibited
a comparable biphasic expression (Fig. S3).
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We assessed expression of TWEAK ligand and Fn14 receptor
in a transgenic model of CCA induction, where CCA develops
during TAA treatment in livers with CK19-inducible Cre-
recombinase driven p53-deficiency, but not in mice with at
least 1 functional p53 allele (Fig. 2D28). TAA-treated K19-p53f/f
mice significantly increased TWEAK and Fn14 mRNA (Fig. 2E) and
Fn14 protein levels (Fig. 2F) during CCA formation, compared to
mice without CCA (p53WT/het).
These data associate the transition of normal duct epithelium
to iCCA with upregulation of the TWEAK/Fn14 pathway and
suggest a potential function during development and mainte-
nance in multi-species CCA.
TWEAK/Fn14 modulates NF-jB-regulated cytokine/
chemokine secretion in CCA cells
To assess the function of TWEAK/Fn14 in CCA epithelia, we
studied the effects of recombinant human TWEAK (rhTWEAK)
treatment in 4 well-characterised iCCA cell lines, all expressing
cell surface Fn14 (Fig. S4A). TWEAK stimulation uniformly
induced canonical p65 NF-jB phosphorylation, processing of
non-canonical NF-jB p100 to p52 in CC-SW-1 and SNU-1079
cells (Fig. 3A), and stimulated nuclear translocation of p65 in
CCA cells (Fig. 3B). Despite consistent rhTWEAK-mediated NF-jB
activation in all cell lines, only SNU-1079 and HuH-28 cells dis-
played a mitogenic response to rhTWEAK (Fig. 3C).
NF-jB regulates a variety of proinflammatory and pro-
fibrogenic responses in liver disease.29 Since a key element of
CCA development is the formation of a stimulatory, pro-
tumorigenic niche, we investigated TWEAK-induced gene
expression changes in CCA cells. We observed TWEAK-inducible
mRNA expression of monocyte chemoattractant protein 1 (MCP-
1; 3/4 cell lines), (C-X3-C motif) ligand 1 (CX3CL1; 3/4 cell lines),
interleukin (IL)-6 (1/4 cell lines), IL-8 (3/4 cell lines), macrophage
colony-stimulating factor (M-CSF; 3/4 cell lines) and granulocyte
macrophage colony-stimulating factor (GM-CSF; 2/4 cell lines)
(Fig. 3D). To determine pathway specificity, we assessed TWEAK-
inducible gene expression in the presence and absence of in-
hibitors of canonical or non-canonical NF-jB signalling in CCA vs.
HCC cells. Generally, TWEAK-induced gene expression was sub-
dued by canonical NF-jB inhibition in CCA lines. IL-6 was
inhibited by both inhibitors, whereas CX3CL1 and M-CSF were
not affected by either inhibitor in CC-SW-1 cells. Likewise,
CX3CL1 expression was not affected by either inhibitor in HuH-
28 cells. TWEAK-induced gene expression was not observed in
HepG2 HCC cells (Fig. S4B).
We observed significantly increased TWEAK-induced secre-
tion of MCP-1 (all cell lines), IL-8 (2/4 cell lines) and GM-CSF (all
cell lines) into the cell culture medium (Fig. 3E). We also char-
acterised proteins present in conditioned medium from PBS- or
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Fig. 1. TWEAK/Fn14 expression in iCCA. (A) Fn14 immunohistochemistry in archival paraffin sections of patient-matched iCCA vs. non-involved areas of SL (n =
42 iCCA vs. n = 26 SL) (B) Quantification of Fn14 immunostaining (Mann-Whitney U test). (C) Single cell RNA-sequencing data of iCCA (GSE125449; n = 5 per
cohort). Cell types: B-cells, CAFs, HPCs, Malig., TAMs, T cells, TECs, undefined. (D) Staining of Fn14 (red) in tumour cells (PanCK; white) and CAFs (aSMA; green) in
an iCCA tissue microarray. Nuclei are stained with DAPI (blue). Proportion of Fn14+ tumour cells (n = 84) and CAFs (n = 74) by tumour grade (Kruskal-Wallis test
with Dunn’s multiple comparison test). Data are mean ± SEM. *p<0.05, **p<0.01. Scale bars represent 100 lm. CAFs, cancer-associated fibroblasts; HPCs, hepatic
progenitor cells; iCCA, intrahepatic cholangiocarcinoma; Malig., malignant cells; SL, surrounding liver; TAMs, tumour-associated macrophages; TECs, tumour
endothelial cells;
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that were present in both PBS- and TWEAK-treated conditioned
medium, or in TWEAK-treated conditioned medium alone, were
assessed for protein-protein interactions and ‘biological process’
gene ontology enrichment (Figs. S5-8). Several gene ontology
terms associated with the development of a pro-tumour micro-
environment were enriched in TWEAK-conditioned medium,
including extracellular matrix development (extracellular matrix
organisation), blood vessel development (angiogenesis, blood
vessel remodelling/development) and immune modulation
(regulation of leukocyte/macrophage chemotaxis, immune sys-
tem process, immune response) in a cell line-specific manner.
These cell line-specific results classified the investigated Fn14+
iCCA lines asTWEAK-high responder (CC-SW-1andSNU-1079) and
TWEAK-low responder cell lines (CC-LP-1 and HuH-28) and pro-
vided evidence that TWEAK/Fn14 may play a role in the develop-
ment of CCA by orchestrating the surrounding niche via localised
NF-jB-mediated chemokine/cytokine secretion.
TWEAK-induced CCA-derived factors regulate macrophage
biology
TAMs play a critical role in providing pro-proliferative and pro-
survival factors in CCA.7 Since TWEAK induces the secretion of
several proinflammatory proteins in CCA cells, we investigated
whether any of these TWEAK-induced, CCA-derived secreted
proteins could affect macrophage phenotypes. To model the ef-
fect of TWEAK in CCA-induced patterning of macrophages in the
CCA niche, we isolated human peripheral blood monocytes
(Fig. S9A), differentiated these cells into macrophages (human
monocyte-derived macrophages [HMDMs]) and subjected them
to (a) PBS-supplemented basal medium vs. (b) TWEAK-
supplemented basal medium, to assess the direct effects of
TWEAK on HMDMs; or to (c) conditioned medium from PBS-
treated CCA cell lines vs. (d) conditioned medium from
TWEAK-treated CCA cell lines, to measure the indirect effects of
A 600 mg/L Thioacetamide (TAA)
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Fig. 2. TWEAK/Fn14 upregulation in rodent CCA. (A) Schematic of TAA treatment of rats to induce CCA. (B) Dual immunofluorescence reveals Fn14+ (green)
tumour epithelia (PanCK+; red). (C) mRNA expression of Fn14 and TWEAK in a time course of TAA treatment in rats (n = 3 to 11; Kruskal-Wallis with Dunn’s post-
test) (D) Schematic of TAA treatment of Krt19-CreERTR26-eYFPp53flox/het/wt mice to induce CCA. (E) mRNA expression of Fn14 and TWEAK in Krt19-CreERTR26-
eYFPp53Fl/WT or Krt19-CreERTR26-eYFPp53WT/WT (p53wt/het; no CCA, n = 9) vs. Krt19-CreERTR26-eYFPp53flox/flox (p53f/f; CCA, n = 6; Mann-Whitney U test). (F)
Protein expression of Fn14 in mouse p53wt/het vs. p53flox/flox mice (n = 7 each; unpaired t-test). Data are mean ± SEM. *p<0.05, **p<0.01.***p<0.001. Scale bars
represent 50 lm. CCA, cholangiocarcinoma; TAA, thioacetamide.
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TWEAK in HMDMs via TWEAK-induced protein secretion in the
CCA cell lines.
HMDM differentiation was confirmed by 25F9 expression
(Fig. S9B). Treatment with conditioned medium from TWEAK-
stimulated TWEAK-high responder CCA lines (CC-SW-1 and
SNU-1079) significantly increased cell surface expression of a
TAM-associated marker, CD206, in HMDMs. No significant dif-
ference was observed when conditioned medium from TWEAK-
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Fig. 3. TWEAK signalling drives NF-jB pathway activation and protein production. (A) TWEAK-dependent modulation of NF-jB pathway proteins in CCA cells
and quantification of NF-jB protein expression 2 h-post rhTWEAK exposure. (B) Localisation of NF-jB p65 subunit in CCA cell lines after TWEAK treatment. (C)
MTT assay in CCA lines following 72 h treatment with increasing dose of rhTWEAK. (D) TWEAK-dependent mRNA expression in CCA lines following 6 h rhTWEAK
treatment. (E) Protein immunoassay of secreted proteins from CCA lines treated with PBS or rhTWEAK. Data are mean ± SEM. unpaired t-test (n = 3) or one-way
ANOVA with Dunnett’s post-test (MTT assay; n = 6); *p<0.05, **p<0.01, ***p<0.001. Scale bars represent 50 lm. CCA, cholangiocarcinoma; rhTWEAK, recombinant
human TWEAK.
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low responder CCA lines (CC-LP-1 and HuH-28 cells) was used
(Fig. 4A), suggesting that TWEAK-induced factors from some
CCA cells can induce macrophage polarisation. We also assessed
mRNA expression of several cytokines, chemokines, growth
factors and receptors. HMDMs expressed 154- to 733-fold less
Fn14 mRNA than CCA/HCC cell lines (Fig. S9C) and did not
modulate gene expression when treated with TWEAK alone
(Fig. 4B). Few genes were differentially regulated in HMDMs
exposed to conditioned medium from the TWEAK-low
responder CCA cells (MMP-2 in TWEAK-conditioned medium
from CC-LP-1 cells, and TWEAK and CD163 mRNA in TWEAK-
conditioned medium from HuH-28 cells). However, expression
of several key transcripts was induced in HMDMs treated with
TWEAK-conditioned medium from CC-SW-1 and SNU-1079
cells. IL-6 was upregulated in TWEAK-conditioned medium
from both cell lines (82.6-fold and 105.2-fold), as was TIMP-1
(4.5-fold and 4.3-fold). In CC-SW-1 conditioned medium-
patterned cells, we observed additional upregulation of CD80
(2.8-fold), M-CSF (6.2-fold) and TNF (3.9-fold). SNU-1079-
patterned cells responded with additional upregulation of
MCP-1 (4.0-fold) and vascular endothelial growth factor-alpha
(VEGF-a; 4.5-fold). We also assessed 2 surface markers associ-
ated with TAMs; triggering receptor expressed on myeloid
cells 2 (TREM-2) and macrophage receptor with collagenous
structure (MARCO). All populations expressed TREM-2, and
SNU-1079-patterned cells upregulated MARCO (18.1-fold;
Fig. 4B).
MCP-1 is upregulated in CCA and affects macrophage
accumulation in the tumour niche
MCP-1 was the most abundant TWEAK-inducible protein pro-
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Fig. 4. CCA-derived TWEAK-inducible factors drive macrophage patterning. (A) Cell surface CD206 expression (MFI) in HMDMs treated with CM from PBS- or
TWEAK-treated CCA cells (One-way ANOVA with Tukey’s post-test; n = 3). (B) mRNA expression in HMDMs treated with CM from PBS- or TWEAK-treated CCA
cells (n = 3). Fold changes expression was calculated compared to control DMEM with PBS (DMEM+PBS) and analysed using one-way ANOVA with Dunnett’s
multiple comparison test. *p<0.05, **p<0.01, ***p<0.001. Data are mean ± SEM. CCA, cholangiocarcinoma; CM, conditioned medium; HMDM, human monocyte-
derived macrophage; MFI, mean fluorescence intensity.
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upregulated in macrophages by TWEAK-inducible factors pro-
duced by CCA cells (Fig. 4). We therefore further investigated
MCP-1 expression in CCA to link in vitro observations to human
disease. In analysis of a single cell RNA-sequencing dataset
(GSE12544926), MCP-1 mRNA was expressed by CAFs, and sub-
sets of tumour cells, HPCs and TAMs, while its cognate receptor
C-C chemokine receptor type 2 (CCR2) was mainly expressed in
TAMs and T cells (Fig. S10A). We observed increased MCP-1
immunostaining in archival human iCCA in tumour epithelia
and widespread expression in stromal cells, compared to a
subset of paired non-involved surrounding liver areas (Fig. 5A),
confirmed by pixel analysis (Fig. 5B).
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Fig. 5. MCP-1 expression in CCA. (A) MCP-1 immunohistochemistry in archival paraffin sections of patient-matched iCCA vs. adjacent non-involved SL areas. (B)
Digital pixel analysis of sections (n = 42 iCCA vs. n = 26 SL; Mann-Whitney U test). (C) Staining of tumour liver tissue from an iCCA tissue microarray (n = 89) with
PanCK (white), Fn14 (red), MCP-1 (green). Nuclei are stained with DAPI (blue). (D) Analysis of total distribution of MCP-1+ cells in Fn14- and Fn14+ subsets of
PanCK+ tumour cells in individual CCA tissues or stratified with respect to tumour grade (Wilcoxon matched-pairs signed rank test). (E) Assessment of distri-
bution in MCP-1+ cells (red) in CD68+ macrophages (green) and aSMA+ CAFs (white). Nuclei are stained with DAPI (blue). Data are mean ± SEM. *p<0.05, **p<0.01,
****p<0.0001. Scale bars represent 100 lm. CAFs, cancer-associated fibroblasts; CCA, cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; SL, surrounding
liver.
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Next, we assessed the co-regulation of the TWEAK/Fn14
pathway and MCP-1 expression in CCA epithelia. We stratified
PanCK+ epithelial tumour cells into Fn14+ and Fn14- subsets,
assessed the distribution of MCP-1+ cells in iCCA and further
assessed these data with respect to tumour grade (Fig. 5C).
Importantly, MCP-1 expression was proportionally higher in
Fn14+ vs. Fn14- iCCA ducts in this cohort (Fig. 5D; n = 89). When
stratified by tumour grade, this distribution was maintained in
moderately differentiated grade 2 tumours (p<0.0001, n = 32;)
and poorly differentiated grade 3 tumours (p = 0.0014, n = 44;
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Fig. 6. MCP-1 in rodent CCA. (A) MCP-1 immunohistochemistry in liver from rats administered TAA for 10 weeks (injured, pre-malignant) up to 26 weeks. (B)
Triple immunofluorescence reveals MCP-1+ tumour epithelia (PanCK+) with interspersed macrophage infiltration (CD68) in rat CCA. (C) mRNA expression ofMCP-
1 in a time course of TAA treatment in rats (n = 3-11 per timepoint; Kruskal-Wallis test with Dunn’s post-test). (D) Triple immunofluorescence reveals MCP-1+
tumour epithelia (PanCK+) with interspersed macrophage infiltration (F4/80+) in Krt19-CreERTR26-eYFPp53Fl/Fl mice administered TAA for 26 weeks to induce
CCA. (E) Schematic of xenograft experiments. (F) SNU-1079 xenografts in CD-1 nude mice treated with control or anti-MCP-1 antibody (n = 8 per group; unpaired
t-test). (G) Macrophage marker (F4/80, CD206) staining of SNU-1079 xenografts (n = 7 isotype vs. n = 6 treated with anti-MCP-1; Mann-Whitney U test). (H)
Analysis of peripheral blood monocytes of xenografted CD-1 nude mice (n = 7 isotype vs. n = 8 anti-MCP-1 treated; unpaired t-test). Data are mean ± SEM. *p<0.05,
**p<0.01, ***p<0.001. Scale bars represent 50 lm. CCA, cholangiocarcinoma; TAA, thioacetamide.
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Fig. 5D). This preferential distribution of MCP-1+ cells to Fn14+
tumour epithelia was also observed in our cohort of archival
sections from patients with iCCA and another commercially
available CCA tissue microarray (Fig. S10B), suggesting an active
TWEAK/Fn14/MCP-1 axis in a significant proportion of CCAs
across 3 independent cohorts.
We further assessed MCP-1 protein expression in 2 key
components of the tumour niche; TAMs (CD68+) and CAFs
(aSMA+). MCP-1 was expressed by 18.26% of CD68+ TAMs and
18.52% of CAFs compared to 27.98% of malignant epithelia in this
cohort of tumours (n = 88-90; Fig. 5E). Having confirmed MCP-1
upregulation in clinical samples, we explored the temporal
modulation and functional significance of MCP-1 upregulation
during CCA development in rodent models.
In rat CCA, small clusters of MCP-1+ cells were detected dur-
ing early tumour development (Fig. 6A). MCP-1 was expressed
specifically in PanCK+ epithelia in tumour niches containing large
areas of accumulated TAMs (CD68+; Fig. 6B). MCP-1 mRNA also
exhibited the bi-phasic expression observed for Fn14, increasing
again after peak Fn14 expression was observed during tumour
formation (Fig. 6C). MCP-1 was also expressed by CCA tumour
cells in our previously described transgenic TAA CCA model28
(Fig. 6D), suggesting a critical, conserved role for MCP-1 during
multi-species CCA development.
To investigate the functional role of MCP-1 in recruiting
macrophages to the CCA niche, we performed pharmacological
blocking experiments using SNU-1079-generated human CCA
cell xenografts (Fig. 6E). Mice receiving multiple injections of
anti-MCP-1 antibody formed significantly smaller tumours
(Fig. 6F), with 2.3-fold fewer intratumoural F4/80+ macrophages
(Fig. 6G), and 2.2-fold fewer CD206+ macrophages (Fig. 6G),
compared to control antibody-treated xenografts. We observed
significantly more circulating MCP-1 receptor (CCR2+) mono-
cytes in anti-MCP-1-treated animals (Fig. 6H). Although subcu-
taneous xenografts do not recapitulate the entire liver
microenvironment, they enable modelling of interactions
CK19          Ki67        DAPI























































































































































































Fig. 7. TWEAK drives CAF proliferation in CCA. CCA was induced in mice with overexpression of Notch intracellular domain and AKT (NICD/AKT) with effects of
TWEAK overexpression (NICD/AKT+TWEAK) assessed. (A) Gross morphology of livers. (B) Haematoxylin & eosin-stained liver sections. (C) Tumour area (Mann-
Whitney U test) and cystic and tumour epithelial area quantification. (D) Staining of biliary tissue (CK19) and phosphorylated NF-kB p65 (p-p65) in normal and
CCA areas. (E) Staining of biliary tissue and proliferation marker (Ki67). (F) Quantification of CAF (aSMA+) area and collagen deposition (Picrosirius red staining).
(G) Staining of CAF (aSMA) and p-p65 or proliferation marker (Ki67). Data are mean ± SEM. *p<0.05, ***p<0.001, ****p<0.0001. Unpaired t-test unless otherwise
stated. Scale bars represent 100 lm. CAF, cancer-associated fibroblast; CCA, cholangiocarcinoma.
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between circulating immune cells and human CCA cells. Thus,
these data provide key functional context on the role of MCP-1
expression in CCA, with in vivo evidence that recruitment of
TAMs occurs via chemoattraction of CCR2+ monocytes.
TWEAK signalling modulation affects tumour formation
in vivo
To characterise the effects of TWEAK on CCA tumour develop-
ment, we used a previously described system of NICD and AKT
overexpression in hepatocytes to induce CCA in 6 weeks (com-
bination referred to as NICD/AKT30). We compared tumours in
this model to NICD/AKT tumours overexpressing TWEAK (com-
bination referred to as NICD/AKT+TWEAK). The construct used to
overexpress TWEAK also expressed red fluorescent protein,
facilitating concurrent assessment of the localisation of TWEAK-
overexpressing cells (Fig. S11A). Macroscopic white, cyst-like
lesions were observed on the surface of NICD/AKT livers
(Fig. 7A and Fig. S12A), analogous to previously published ob-
servations.30 TWEAK overexpression produced striking alter-
ations in the appearance of livers, with sizeable bile-containing
cysts observed on the surface (Fig. 7A, Fig. S12B).
Microscopic histological characterisations of tumours using
blinded assessment by an independent, specialist liver histopa-
thologist revealed features that were consistent with this
model30 tumours consisted of multifocal nodular lesions, often
coalescing, precluding quantification of tumour number. Tu-
mours were variably cystic and micropapillary epithelial neo-
plasms with cytological epithelial features in keeping with
malignancy, with TWEAK overexpression increasing the cystic
content of these tumours (Fig. 7B, Fig. S11B). Formal observer-
independent quantification of tumour elements showed that
TWEAK overexpression increased the total tumour area and
cystic percentage of tumours (Fig. 7C). The tumour epithelial area
was not altered by TWEAK overexpression (Fig. 7C). Accordingly,
CK19+ epithelium with active, nuclear localisation of phosphor-
ylated NF-jB p65 in either bile duct or CCA tissue was similar in
both conditions (Fig. 7D), and most CCA cells were proliferating
(Ki67+; Fig. 7E), presumably as a result of AKT overexpression.30
We did not find an association between the tumour cystic grade
and the proportion of Fn14+ cells in CCA cells or CAFs in patient
tissues (Fig. S13).
Complementing our xenograft results, we observed increases
in innate immune cells with TWEAK overexpression, including
CD11b+ monocyte/neutrophils that clustered within the tumour
niche in cystic tumour areas (Fig. S11C), and a 2-fold increase in
CD206+ macrophage numbers (Fig. S11C), as well as upregulation
of GM-CSF in the liver and plasma (Fig. S11D).
TWEAK overexpression also significantly affected the CAF
subcompartment of the CCA niche, previously shown to express
Fn14+ in patient iCCAs (Fig. 1). We detected a 1.32-fold increase
in the aSMA+ CAF area and the Picrosirius red-positive collagen
area in NICD/AKT+TWEAK tumours (Fig. 7F). TWEAK activation
of canonical NF-jB signalling, demonstrated by an increased
proportion of CAFs expressing nuclear phospho-p65 (Fig. 7G),
has previously been shown to drive hepatic stellate cell prolif-
eration in chronic liver injury.23 We observed a 1.53-fold increase
in proliferating Ki67+/aSMA+ CAFs in TWEAK-overexpressing
CCAs (Fig. 7G).
Having established novel roles of TWEAK in inflammatory
and fibrogenic niche development in CCA, critical components of
a tumour-permissive environment,31 we assessed TAA-mediated
chronic liver disease in homozygous Fn14 knockout mice
compared to wildtype Fn14-expressing littermate controls
(Fig. S14A). Following 6 months of TAA injury, significant
macroscopic tumour formation was observed in Fn14 wildtype
mice (12/12 animals with 1 or multiple tumours; 2, <2 mm; 9, 2-
5 mm, 1, >5 mm diameter), while 1/9 Fn14 knockout mice dis-
played an early tumour of less than 2 mm in diameter (Fig. S14B).
Concomitant with tumour inhibition in Fn14 knockout mice, we
observed a reduction in PanCK+ cells as well as F4/80+ and
CD206+ macrophages (Fig. S14C, 14 D). MCP-1, GM-CSF, IL-6 and
KC/Gro remained at steady-state levels in 6-month TAA-treated
mice (Fig. S14E). These data support our hypothesis that
TWEAK/Fn14 signalling supports hepatic tumour development
by playing a pivotal role in niche establishment during chronic
liver injury.
Discussion
During chronic liver injury, macrophage-produced TWEAK
drives proliferation of Fn14+ cholangiocytes (to initiate hepatic
regeneration21,22,32) and aSMA+ myofibroblasts (affecting extra-
cellular matrix deposition in damaged liver areas by regulating
their cell numbers23,24). Macrophages comprise the majority of
the inflammatory cell infiltrate in the CCA stroma,15–17,19
providing key signals (such as Wnt ligands) to induce growth
and apoptosis resistance,6,7 as well as cytokines (including IL-6,
TNF and TGF-b1) to promote metastatic progression.15,17 We
hypothesised that TWEAK/Fn14-induced downstream signalling
represents a significant pathway, supporting CCA growth and
maintenance.
Through corroboration of transcriptomic data from multiple
independent CCA patient cohorts and characterisation of patient
samples, we demonstrated upregulation of Fn14 in CCA, on
tumour epithelial cells and CAFs, compared to non-involved liver
tissue. Significantly, a subset of TWEAK-expressing TAMs local-
ised within the CCA niche, suggesting interplay between ligand-
expressing niche and receptor-expressing tumour/niche via
TWEAK/Fn14, potentiating therapeutic targeting. We demon-
strated that TWEAK/Fn14 pathway elements are progressively
upregulated in rodent CCA tissues. Previous studies reported
proliferation of biliary epithelial, and HCC cells, in response to
TWEAK.21,22,25,32 We explored the effects of TWEAK in CCA lines
and found that TWEAK modulated NF-jB signalling in all
investigated CCA cell lines, but not HepG2 HCC cells. However,
this signal led to cell line-specific cellular responses, suggesting
more complex functions for TWEAK/Fn14 signalling in CCA.
In chronic injury, NF-jB controls the expression of a multi-
tude of chemokines and growth factors that regulate liver
inflammation and repair, including MCP-1,33 while aberrant
expression of NF-jB pathway components results in sponta-
neous liver fibrosis and eventual HCC in genetic mouse
models.34–36 Although TWEAK-responsive NF-jB pathway acti-
vation was seen in all CCA cell lines we assessed, we did not
observe consistent proliferative effects, as reported in other liver
cell types.21,22,25 In response to TWEAK stimulation, CCA cells
secreted proinflammatory chemokines and growth factors, sug-
gesting TWEAK can regulate CCA niche development. We further
explored the functional role of MCP-1, which drives inflamma-
tory macrophage recruitment to sites of liver injury via its re-
ceptor CCR2.37,38 Disrupting MCP-1/CCR2 has proven effective in
inhibiting TAM accumulation and tumour development in pre-
clinical HCC models.39,40 We observed in vitro TWEAK-inducible
Journal of Hepatology 2021 vol. 74 j 860–872 869
MCP-1 expression and detected MCP-1 in tumour cells in multi-
species CCA. MCP-1 inhibition reduced SNU-1079 xenograft size,
with accumulation of CCR2+ monocytes in peripheral blood and
decreased TAMs, providing evidence for an MCP-1-mediated
macrophage recruitment to the tumour niche by CCA cells.
Further support for this axis having a functional role is provided
by our data from TAA-treated Fn14 knockout mice, which dis-
played significantly reduced macrophages and drastically
inhibited or delayed tumorigenesis.
We also report a novel function of TWEAK in the liver in
driving the secretion of factors from CCA cells that alter
macrophage phenotype. CCA cells actively educated macro-
phages towards a TAM-like phenotype, expressing a mixture of
classically activated and alternative activation markers, as well
as upregulating molecules involved in matrix remodelling.18 In
TWEAK-high responsive CCA cell lines (SNU-1079 and CC-SW-
1), we observed an increased ability to pattern macrophages
towards a TAM-like ‘M2-skewed’ phenotype with CD206 and
proinflammatory gene expression including IL-6, TNF and MCP-
1, reminiscent of TAMs observed in CCA.7,17,19 Additionally, CCA-
patterned macrophages also upregulated the scavenger recep-
tor MARCO, a marker of immunosuppressive TAMs in many
tumour types.41 Data from progressive CCA in rats demon-
strated that Fn14 and MCP-1 upregulation is co-regulated early
in CCA development. Furthermore, TWEAK overexpression in
CCA promoted a dramatic alteration in tumour phenotype by
inducing expansion of collagen-producing CAFs, which express
Fn14 in a significant proportion of patient iCCAs. By driving
inflammatory chemokine production, altering macrophage
phenotype via crosstalk with CCA epithelia and promoting
fibroblastic growth within the CCA microenvironment via a
direct action of TWEAK on CAF proliferation, upregulation of
TWEAK/Fn14 signalling appears to be an early driver, promot-
ing the development of a niche that supports tumour growth.
Our data using genetic knockout or antibody inhibition of
TWEAK downstream events highlight the potential for clinically
relevant therapeutic targeting. A humanised antibody against
TWEAK, RG7212, is currently being investigated for its efficacy
in treating late-stage Fn14+ solid tumours in malignancies
including colorectal cancer, melanoma and a cohort of 3 pa-
tients with CCA, with antibody treatment well-tolerated.
Notably, one of the desired actions of antibody treatment is to
reduce serum MCP-1 levels.42,43
In addition to affecting the CAF and TAM niche compart-
ments, we also report TWEAK-induced secretion of molecules
involved in blood vessel development and angiogenesis from
CCA cell lines. Macrophages patterned by TWEAK-inducible
factors from SNU-1079 cells also upregulated VEGF-a mRNA.
Significantly, VEGF-A and VEGF-C from CAFs are important me-
diators of lymphangiogenesis in CCA,44 which is correlated with
poor patient outcomes.45 We also observed some vascular Fn14
expression in rat and human CCA. TWEAK can stimulate endo-
thelial cell proliferation, following Fn14 upregulation in response
to VEGF-A and FGF-2.46 Given our in vitro proteomic and
macrophage patterning results, combined with observation in
patient samples, there is future scope to ascertain the role of
TWEAK/Fn14 signalling in metastatic progression by acting
directly on the endothelium, and indirectly via secretion of
proteins from tumour cells, tumour-conditioned TAMs and CAFs,
which promote tumour progression via pathways such as VEGF-
A and VEGF-C.
Our study provides a detailed and novel mechanistic frame-
work of how the TWEAK/Fn14 pathway is involved in building a
tumour-permissive niche, acting on TAMs and CAFs in CCA,
which both drive chemotherapy resistance.47 Given the signifi-
cant proportion of patients with CCA exhibiting aberrant upre-
gulation of Fn14, targeting TWEAK/Fn14 may provide avenues to
interrupt epithelial-stromal crosstalk to create novel therapeu-
tics for a cancer where effective treatments are urgently
required.
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